Advanced Renal Cell Carcinoma Completed Phase 2 Trials for Trebananib (DB12056)

Also known as: Advanced Renal cell carcinoma

IndicationStatusPhase
DBCOND0032596 (Advanced Renal Cell Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00853372AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With SunitinibTreatment
NCT00467025AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With SorafenibTreatment